132 related articles for article (PubMed ID: 38509646)
1. Prognostic impact of limited resection vs. inadequate adjuvant therapy in patients with pathologic stage II or III non-small cell lung cancer: results from the Korean Association of Lung Cancer Registry.
Lee J; Cho JS; Kim YD; Ahn HY; ;
Ann Palliat Med; 2024 Mar; 13(2):230-239. PubMed ID: 38509646
[TBL] [Abstract][Full Text] [Related]
2. Topoisomerase II alpha expression and the benefit of adjuvant chemotherapy for postoperative patients with non-small cell lung cancer.
Yan S; Shun-Chang J; Li C; Jie L; Ya-Li L; Ling-Xiong W
BMC Cancer; 2010 Nov; 10():621. PubMed ID: 21067592
[TBL] [Abstract][Full Text] [Related]
3. Impact of thymosin α1 as an immunomodulatory therapy on long-term survival of non-small cell lung cancer patients after R0 resection: a propensity score-matched analysis.
Guo CL; Mei JD; Jia YL; Gan FY; Tang YD; Liu CW; Zeng Z; Yang ZY; Deng SY; Sun X; Liu LX
Chin Med J (Engl); 2021 Nov; 134(22):2700-2709. PubMed ID: 34732663
[TBL] [Abstract][Full Text] [Related]
4. Impact of age on adjuvant chemotherapy after radical resection in patients with non-small cell lung cancer.
Zhai X; Yang L; Chen S; Zheng Q; Wang Z
Cancer Med; 2016 Sep; 5(9):2286-93. PubMed ID: 27367482
[TBL] [Abstract][Full Text] [Related]
5. Sublobar Resection versus Stereotactic Body Radiation Therapy for Clinical Stage I Non-Small Cell Lung Cancer: A Study Using Data from the Korean Nationwide Lung Cancer Registry.
Yun J; Cho JH; Hong TH; Yang K; Ahn YC; Kim HK; ;
Cancer Res Treat; 2023 Oct; 55(4):1171-1180. PubMed ID: 37080606
[TBL] [Abstract][Full Text] [Related]
6. Prognostic potential of ERCC1 protein expression and clinicopathologic factors in stage III/N2 non-small cell lung cancer.
Yan D; Wei P; An G; Chen W
J Cardiothorac Surg; 2013 Jun; 8():149. PubMed ID: 23759026
[TBL] [Abstract][Full Text] [Related]
7. Advantage of post-operative oral administration of UFT (tegafur and uracil) for completely resected p-stage I-IIIa non-small cell lung cancer (NSCLC).
Tanaka F; Miyahara R; Ohtake Y; Yanagihara K; Fukuse T; Hitomi S; Wada H
Eur J Cardiothorac Surg; 1998 Sep; 14(3):256-62; discussion 263-4. PubMed ID: 9761434
[TBL] [Abstract][Full Text] [Related]
8. Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
Howington JA; Blum MG; Chang AC; Balekian AA; Murthy SC
Chest; 2013 May; 143(5 Suppl):e278S-e313S. PubMed ID: 23649443
[TBL] [Abstract][Full Text] [Related]
9. CT derived radiomic score for predicting the added benefit of adjuvant chemotherapy following surgery in stage I, II resectable non-small cell lung cancer: a retrospective multicohort study for outcome prediction.
Vaidya P; Bera K; Gupta A; Wang X; Corredor G; Fu P; Beig N; Prasanna P; Patil PD; Velu PD; Rajiah P; Gilkeson R; Feldman MD; Choi H; Velcheti V; Madabhushi A
Lancet Digit Health; 2020 Mar; 2(3):e116-e128. PubMed ID: 33334576
[TBL] [Abstract][Full Text] [Related]
10. Lobe-specific analysis of perioperative chemotherapy for non-small cell lung cancer patients.
Lei X; Li T; Mao F; Ren F; Tang Q; Cao W; Zu L; Xu S
Cancer Med; 2023 Aug; 12(16):16896-16905. PubMed ID: 37403701
[TBL] [Abstract][Full Text] [Related]
11. Postoperative adjuvant chemotherapy and radiotherapy for stage II and III non-small cell lung cancer (NSCLC).
Lee SW; Choi EK; Chung WK; Shin KH; Ahn SD; Kim JH; Kim SW; Suh C; Lee JS; Kim WS; Kim DS; Kim DK; Park SI; Sohn KH
Lung Cancer; 2002 Jul; 37(1):65-71. PubMed ID: 12057869
[TBL] [Abstract][Full Text] [Related]
12. Influence of adjuvant chemotherapy on survival for patients with stage IB and IIA non-small cell lung cancer.
Zhang P; Duan J; Bai H; Wang Z; Gao S; Tan F; Gao Y; Wang X; Wan R; Xu J; He X; Feng X; Yu R; Sun J; Zhao Z; Fei K; Li N; He J; Wang J
Thorac Cancer; 2021 Jan; 12(1):30-39. PubMed ID: 33111432
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant chemotherapy uptake in non-small cell lung cancer.
Younis T; Al-Fayea T; Virik K; Morzycki W; Saint-Jacques N
J Thorac Oncol; 2008 Nov; 3(11):1272-8. PubMed ID: 18978562
[TBL] [Abstract][Full Text] [Related]
14. Association of Delayed Adjuvant Chemotherapy With Survival After Lung Cancer Surgery.
Salazar MC; Rosen JE; Wang Z; Arnold BN; Thomas DC; Herbst RS; Kim AW; Detterbeck FC; Blasberg JD; Boffa DJ
JAMA Oncol; 2017 May; 3(5):610-619. PubMed ID: 28056112
[TBL] [Abstract][Full Text] [Related]
15. A phase II randomized trial of adjuvant chemotherapy with S-1 versus S-1 plus cisplatin for completely resected pathological stage II/IIIA non-small cell lung cancer.
Okamoto T; Yano T; Shimokawa M; Takeo S; Yamazaki K; Sugio K; Takenoyama M; Nagashima A; Tsukamoto S; Hamatake M; Yokoyama H; Ueda H; Motohiro A; Tagawa T; Shoji F; Kometani T; Saito G; Fukuyama Y; Toyokawa G; Osoegawa A; Emi Y; Maehara Y;
Lung Cancer; 2018 Oct; 124():255-259. PubMed ID: 30268470
[TBL] [Abstract][Full Text] [Related]
16. Major clinical benefit from adjuvant chemotherapy for stage II-III non-small cell lung cancer patients aged 75 years or older: a propensity score-matched analysis.
Blasi M; Eichhorn ME; Christopoulos P; Winter H; Heußel CP; Herth FJ; El Shafie R; Kriegsmann K; Kriegsmann M; Stenzinger A; Bischoff H; Thomas M; Kuon J
BMC Pulm Med; 2022 Jun; 22(1):255. PubMed ID: 35761214
[TBL] [Abstract][Full Text] [Related]
17. Role of postoperative radiotherapy after curative resection and adjuvant chemotherapy for patients with pathological stage N2 non-small-cell lung cancer: a propensity score matching analysis.
Kim BH; Kim HJ; Wu HG; Kang CH; Kim YT; Lee SH; Kim DW
Clin Lung Cancer; 2014 Sep; 15(5):356-64. PubMed ID: 24996882
[TBL] [Abstract][Full Text] [Related]
18. Optimal Adjuvant Therapy in Resected Stage IIIA-N2 Non-Small-Cell Lung Cancer Harboring EGFR Mutations.
Wen M; Wang L; Wang X; Yang S; Sun Y; Xia J; Zhang Y; Zhang Z; Huang L; Jiang T
Oncol Res Treat; 2020; 43(12):686-693. PubMed ID: 33197924
[TBL] [Abstract][Full Text] [Related]
19. Defining outcomes of patients with clinical stage I small cell lung cancer upstaged at surgery.
Thomas DC; Arnold BN; Rosen JE; Salazar MC; Blasberg JD; Detterbeck FC; Boffa DJ; Kim AW
Lung Cancer; 2017 Jan; 103():75-81. PubMed ID: 28024700
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial.
Wakelee HA; Dahlberg SE; Keller SM; Tester WJ; Gandara DR; Graziano SL; Adjei AA; Leighl NB; Aisner SC; Rothman JM; Patel JD; Sborov MD; McDermott SR; Perez-Soler R; Traynor AM; Butts C; Evans T; Shafqat A; Chapman AE; Kasbari SS; Horn L; Ramalingam SS; Schiller JH;
Lancet Oncol; 2017 Dec; 18(12):1610-1623. PubMed ID: 29129443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
